PsychonautWiki Archive

5-MAPB: Difference between revisions

← Older editNewer edit →
>White
m Text replacement - "{{Main|Research chemicals#Toxicity and harm potential}}" to "{{Further|Research chemicals#Toxicity and harm potential}}"
>Melunaka
m →Legal status: Fix typo
(20 intermediate revisions by 13 users not shown)
Line 1: Line 1:
{{proofread}}


{{SummarySheet}}
{{SubstanceBox/5-MAPB}}
{{SubstanceBox/5-MAPB}}
{|
 
|-
|-
| ''[[ 5-MAPB/Summary|Summary sheet:  5-MAPB]]''
|}
'''5-(2-methylaminopropyl)benzofuran''' (abbreviated '''5-MAPB''') is a synthetic [[Psychoactive class::entactogen]] of the substituted [[chemical class::benzofuran]] class of chemicals, which are known to produce [[euphoria|euphoric]], [[entactogen]]ic, [[stimulant|stimulating]] and mildly [[hallucinogen]]ic effects. These include such [[MDA]]-inspired substances as [[5-APB]], [[6-APB]] and [[5-EAPB]], among others. 5-MAPB is the N-methylated form of [[5-APB]], analogously to how [[MDMA]] is the N-methylated form of [[MDA]].
'''5-(2-methylaminopropyl)benzofuran''' (abbreviated '''5-MAPB''') is a synthetic [[Psychoactive class::entactogen]] of the substituted [[chemical class::benzofuran]] class of chemicals, which are known to produce [[euphoria|euphoric]], [[entactogen]]ic, [[stimulant|stimulating]] and mildly [[hallucinogen]]ic effects. These include such [[MDA]]-inspired substances as [[5-APB]], [[6-APB]] and [[5-EAPB]], among others. 5-MAPB is the N-methylated form of [[5-APB]], analogously to how [[MDMA]] is the N-methylated form of [[MDA]].


This compound is known for its [[stimulating]], [[euphoria|euphoric]] and [[entactogen]]ic effects that is capable of acting a quasi-substitute for [[MDMA]] proper, which has resulted in its rise in popularity as a [[research chemical]] that is easily accessible through the use of online vendors. It has been sold as a [[designer drug]] since 2010.<ref>EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | http://www.emcdda.europa.eu/publications/implementation-reports/2010</ref>
This compound is known for its [[stimulating]], [[euphoria|euphoric]] and [[entactogen]]ic effects that is capable of acting a quasi-substitute for [[MDMA]] proper, which has resulted in its rise in popularity as a [[research chemical]] that is easily accessible through the use of online vendors. It has been sold as a [[designer drug]] since 2010.<ref>{{Citation | title=EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | url=https://www.emcdda.europa.eu/publications/implementation-reports/2010}}</ref>


5-MAPB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 10% more potent by mass so doses should be adjusted accordingly.{{citation needed}}
5-MAPB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 36% more potent by mass so doses should be adjusted accordingly.{{citation needed}}


==Chemistry==
==Chemistry==
Line 17: Line 13:


==Pharmacology==
==Pharmacology==
5-MAPB is a triple [[reuptake inhibitor]] for the [[monoamines]] [[norepinephrine]], [[dopamine]] and [[serotonin]] as well as being an [[agonist]] for the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] and [[Serotonin#The_5-HT_system|5-HT<sub>2B</sub>]] [[receptor]]s.<ref>The effects of benzofury (5-MAPB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24012617?dopt=Abstract</ref><ref>Neurochemical profiles of some novel psychoactive substances (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299912010114</ref> It has also been speculated that 5-MAPB acts as a [[releasing agent]] for the previously mentioned [[neurotransmitters]].
5-MAPB is a triple [[reuptake inhibitor]] for the [[monoamines]] [[norepinephrine]], [[dopamine]] and [[serotonin]] as well as being an [[agonist]] for the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] and [[Serotonin#The_5-HT_system|5-HT<sub>2B</sub>]] [[receptor]]s.<ref>{{cite journal | vauthors=((Dawson, P.)), ((Opacka-Juffry, J.)), ((Moffatt, J. D.)), ((Daniju, Y.)), ((Dutta, N.)), ((Ramsey, J.)), ((Davidson, C.)) | journal=Progress in Neuro-Psychopharmacology & Biological Psychiatry | title=The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat | volume=48 | pages=57–63 | date=3 January 2014 | issn=1878-4216 | doi=10.1016/j.pnpbp.2013.08.013}}</ref><ref>{{cite journal | vauthors=((Iversen, L.)), ((Gibbons, S.)), ((Treble, R.)), ((Setola, V.)), ((Huang, X.-P.)), ((Roth, B. L.)) | journal=European Journal of Pharmacology | title=Neurochemical profiles of some novel psychoactive substances | volume=700 | issue=1 | pages=147–151 | date=30 January 2013 | url=https://www.sciencedirect.com/science/article/pii/S0014299912010114 | issn=0014-2999 | doi=10.1016/j.ejphar.2012.12.006}}</ref> It has also been speculated that 5-MAPB acts as a [[releasing agent]] for the previously mentioned [[neurotransmitters]].


As a result, releasing agents such as [[5-MAPB]] may exert their activity by effectively boosting the levels of the serotonin, norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear and reuptake those monoamines from the synaptic cleft. This allows serotonin, dopamine and norepinephrine to accumulate within various reward and cognition-related areas in the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects.
As a result, releasing agents such as [[5-MAPB]] may exert their activity by effectively boosting the levels of the serotonin, norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear and reuptake those monoamines from the synaptic cleft. This allows serotonin, dopamine and norepinephrine to accumulate within various reward and cognition-related areas in the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects.
Line 24: Line 20:
{{effectStub}}
{{effectStub}}
{{Preamble/SubjectiveEffects}}                                                                             
{{Preamble/SubjectiveEffects}}                                                                             
===Physical effects===
 
*'''[[Effect::Stimulation]]''' -  In terms of its effects on the user's physical energy levels, 5-MAPB is commonly regarded as significantly less stimulating and energizing than MDMA, while still retaining its core entactogenic effects. Unlike MDMA, which encourages activities such as running, climbing and dancing in a way that makes it a popular choice for musical events such as festivals and raves. The distinct style of stimulation which 5-MAPB presents can be described as mildly to moderately forced, trending more towards sedation and relaxation. This means that at higher doses, it becomes difficult or impossible to keep still as jaw clenching, involuntarily body shakes and vibrations become present, resulting in an extreme unsteadiness of the hands and a general lack of motor control, though to a far lesser degree than with MDMA.
{{effects/base
|{{effects/physical|
*'''[[Effect::Stimulation]]''' -  In terms of its effects on the user's physical energy levels, 5-MAPB is commonly regarded as significantly less stimulating and energizing than MDMA, while still retaining its core entactogenic effects. Unlike MDMA, which encourages activities such as running, climbing and dancing in a way that makes it a popular choice for musical events such as festivals and raves, the distinct style of stimulation which 5-MAPB presents can be described as mildly to moderately forced, trending more towards sedation and relaxation. This means that at higher doses, it becomes difficult or impossible to keep still as jaw clenching, involuntarily body shakes and vibrations become present, resulting in an extreme unsteadiness of the hands and a general lack of motor control, though to a far lesser degree than with MDMA.
*'''[[Effect::Increased heart rate]]'''
*'''[[Effect::Increased heart rate]]'''
*'''[[Effect::Dehydration]]'''
*'''[[Effect::Dehydration]]'''
Line 32: Line 30:
*'''[[Effect::Temporary erectile dysfunction]]'''
*'''[[Effect::Temporary erectile dysfunction]]'''
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Nystagmus]]'''
}}
{{effects/visual|
*'''[[Effect::Acuity enhancement]]'''
}}
|{{effects/cognitive|
The cognitive effects of 5-MAPB are mostly comparable to [[MDMA]], but missing the physical and mental stimulation that would be associated. Instead, it focuses mostly on serotonergic activity, leading to more pronounced feelings of empathy, euphoria and a general relaxed state of mind. At higher dosages, this becomes less apparent as physical and cognitive side effects appear which can result in states of confusion and restlessness perhaps more severe than with MDMA. It also shares many of its effects with [[5-APB]].


===Cognitive effects===
*'''[[Effect::Empathy, love, and sociability enhancement]]'''
*'''[[Effect::Empathy, love, and sociability enhancement]]'''
*'''[[Effect::Focus enhancement]]'''  
*'''[[Effect::Focus enhancement]]'''  
Line 45: Line 53:
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Increased music appreciation]]'''


===Visual effects===
}}
*'''[[Effect::Acuity enhancement]]'''


===After effects===
{{effects/aftereffects|
The effects which occur during the [[offset]] of a [[stimulant]] experience generally feel negative and uncomfortable in comparison to the effects which occurred during its [[peak]]. This is often referred to as a "comedown" and occurs because of [[neurotransmitter]] depletion. Its effects commonly include:
The effects which occur during the [[offset]] of a [[stimulant]] experience generally feel negative and uncomfortable in comparison to the effects which occurred during its [[peak]]. This is often referred to as a "comedown" and occurs because of [[neurotransmitter]] depletion. Its effects commonly include:
*'''[[Effect::Anxiety]]'''
*'''[[Effect::Anxiety]]'''
Line 57: Line 64:
*'''[[Effect::Thought deceleration]]'''  
*'''[[Effect::Thought deceleration]]'''  
*'''[[Effect::Wakefulness]]'''
*'''[[Effect::Wakefulness]]'''
}}


}}
===Experience reports===
===Experience reports===
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
{{#ask: [[Category:5-MAPB]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:5-MAPB]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_5APB.shtml Erowid Experience Vaults: 5-MAPB]
 
*[https://www.erowid.org/experiences/subs/exp_5MAPB.shtml Erowid Experience Vaults: 5-MAPB]


==Toxicity and harm potential==
==Toxicity and harm potential==
Line 83: Line 93:
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Stimulants|self=5-MAPB}}
{{DangerousInteractions/Stimulants|self=5-MAPB}}
{{DangerousInteractions/MAOI|nt=dopamine}}
{{DangerousInteractions/MAOI|nt=dopamine}}
*'''[[Stimulants]]''' - The neurotoxic effects of 5-MAPB may be increased when combined with other stimulants.
 
*'''[[Cocaine]]''' - This combination may increase strain on the heart.
====[[Serotonin syndrome]] risk====
====[[Serotonin syndrome]] risk====
{{DangerousInteractions/SerotoninSyndrome}}
{{DangerousInteractions/SerotoninSyndrome}}


==Legal issues==
==Legal status==
{{legalStub}}
{{legalStub}}
*'''United Kingdom:''' 5-MAPB is a Class B drug.
 
*'''United States:''' 5-MAPB could be considered an analogue of [[MDA]] and therefore would be covered under the Federal Analogue Act if intended for human consumption.
*'''France''': 5-MAPB is classified as a narcotic since May 9, 2018, alongside other substances derived from benzofuran.<ref>{{cite web|url=https://www.legifrance.gouv.fr/loda/article_lc/LEGIARTI000043529751|title=Article Annexe IV - Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants|publisher=Légifrance|access-date=September 23, 2022|language=fr}}</ref>
*'''Germany''': 5-MAPB is controlled under the NpSG (New Psychoactive Substances Act)<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> as of November 26, 2016.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518|title=Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|publisher=Bundesanzeiger Verlag|access-date=December 18, 2019|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref>
*'''Japan''': 5-MAPB is a controlled substance in Japan effective August 15th, 2015.<ref>[https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/ihou-drug/20140815.html "平成26年8月15日付けで以下の21物質が指定薬物に指定されました。（施行日：平成26年8月25日）"] (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved on May 2, 2022.</ref>
*'''Luxembourg:''' 5-MAPB is not cited in the list of prohibited substances<ref>Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie. | <nowiki>http://legilux.public.lu/eli/etat/leg/loi/1973/02/19/n1/jo</nowiki></ref>. Therefore, it is still a legal substance.
*'''Switzerland''': 5-MAPB is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': 5-MAPB is a Class B drug.
*'''United States''': 5-MAPB could be considered an analogue of [[MDA]] and therefore would be covered under the Federal Analogue Act if intended for human consumption.


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Designer drug]]
*[[Designer drug]]
Line 106: Line 123:


==External links==
==External links==
*[http://drugs.tripsit.me/5-MAPB 5-MAPB (Tripsit)]
 
*[https://en.wikipedia.org/wiki/5-MAPB 5-MAPB (Wikipedia)]
*[https://en.wikipedia.org/wiki/5-MAPB 5-MAPB (Wikipedia)]
*[https://www.erowid.org/chemicals/5-mapb/ 5-MAPB (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=1289 5-MAPB (Isomer Design)]
*[http://www.bluelight.org/vb/threads/548570-The-Big-amp-Dandy-5-MAPB-Thread The Big and Dandy 5-MAPB Thread (Bluelight)]
*[http://www.bluelight.org/vb/threads/548570-The-Big-amp-Dandy-5-MAPB-Thread The Big and Dandy 5-MAPB Thread (Bluelight)]


Line 115: Line 134:
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Amphetamine]]
[[Category:Benzofuran]]
[[Category:Entactogen]]
[[Category:Entactogen]]
[[Category:Stimulant]]
[[Category:Stimulant]]
[[Category:Benzofuran]]
Retrieved from "http://psy.st/wiki/5-MAPB"